The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AGBAYRY ... Eylea sales have been under pressure for some time now due to competition from Vabysmo. We note that Vabysmo ...

Roche plans to invest as much as $550 million in its Indianapolis diagnostics campus during the next five years, with plans to build it into a U.S. | The announcement follows a five-year, $50 billion ...

Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to increased competition from other drugs like Roche’s RHHBY Vabysmo ... unit of Bayer AG BAYRY.

Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY ... for some time now due to competition from Vabysmo. We note that Vabysmo's uptake has been outstanding.

Roche has earmarked more than $700 million to construct a sprawling new plant for its Genentech unit in Holly Springs ... primarily to produce the eye med Vabysmo (known domestically as Luoshijia ...

while its Diagnostics unit brought in CHF 3.5B, mostly unchanged from last year. RHHBY’s multiple sclerosis therapy Ocrevus, eye therapy Vabysmo, and hemophilia therapy Hemlibra drove the pharma ...

Vabysmo, Phesgo Fuel Roche (RHHBY), Pipeline ... back of its robust Battery Management System solutions. Uniform Rental Unit to Aid Cintas (CTAS) amid Rising Costs Per the Zacks analyst, Cintas ...